Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis

Clinical Immunology

Volumn 142, Issue 2, 2012, Pages 150-159

  Papp, Gabor ^a   Horvath, Ildiko Fanny ^a   Barath, Sandor ^a   Gyimesi, Edit ^a   Vegh, Judit ^a   Szodoray, Peter ^b   Zeher, Margit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Clinical effects; Extracorporeal photochemotherapy; Immune regulation; Immunological effects; Systemic sclerosis

Indexed keywords

AMLODIPINE; ANTINUCLEAR ANTIBODY; COMPLEMENT; EXTRACTABLE NUCLEAR ANTIGEN ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 17; METHOXSALEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; SCATTER FACTOR; SCL 70 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG RESPONSE; ECHOGRAPHY; ELBOW FLEXION; EXTRACORPOREAL EXTRACORPOREAL; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; JOINT FUNCTION; KNEE; LUNG FIBROSIS; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NATURAL KILLER T CELL; OUTCOME ASSESSMENT; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; PUVA; REGULATORY T LYMPHOCYTE; SHOULDER; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TH1 CELL; TH17 CELL; TH2 CELL;

ADULT; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; HUMANS; MALE; METHOXSALEN; MIDDLE AGED; PHOTOPHERESIS; SCLERODERMA, SYSTEMIC; SKIN; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84856550315     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.09.014     Document Type: Article

References (26)

1. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 2001, 28:1573-1576.
2. Mayes M.D., Lacey J.V., Beebe-Dimmer J., Gillespie B.W., Cooper B., Laing T.J., Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003, 48:2246-2255.
3. Edelson R.L. Photopheresis: a new therapeutic concept. Yale J. Biol. Med. 1989, 62:565-577.
4. Knobler R.M., French L.E., Kim Y., Bisaccia E., Graninger W., Nahavandi H., Strobl F.J., Keystone E., Mehlmauer M., Rook A.H., Braverman I. Systemic sclerosis study group, a randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J. Am. Acad. Dermatol. 2006, 54:793-799.
5. Hashikabe M., Ohtsuka T., Yamazaki S. Quantitative echographic analysis of photochemotherapy on systemic sclerosis skin. Arch. Dermatol. Res. 2005, 296:522-527.
6. Szodoray P., Papp G., Nakken B., Harangi M., Zeher M. The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation. Autoimmun. Rev. 2010, 9:459-464.
7. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., Rowell N., Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988, 15:202-205.
8. Khanna D., Merkel P.A. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr. Rheumatol. Rep. 2007, 9:151-157.
9. Szodoray P., Gal I., Barath S., Aleksza M., Horvath I.F., Gergely P., Szegedi G., Nakken B., Zeher M. Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand. J. Rheumatol. 2008, 37:205-212.
10. Szodoray P., Papp G., Horvath I.F., Barath S., Sipka S., Nakken B., Zeher M. Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin. Exp. Immunol. 2009, 157:343-349.
11. Horikawa M., Hasegawa M., Komura K., Hayakawa I., Yanaba K., Matsushita T., Takehara K., Sato S. Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J. Invest. Dermatol. 2005, 125:731-737.
12. Riccieri V., Parisi G., Spadaro A., Scrivo R., Barone F., Moretti T., Bernardini G., Strom R., Taccari E., Valesini G. Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J. Rheumatol. 2005, 32:283-286.
13. Papp G., Horvath I.F., Barath S., Gyimesi E., Sipka S., Szodoray P., Zeher M. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand. J. Rheumatol. 2011, 40:205-210.
14. Banica L., Besliu A., Pistol G., Stavaru C., Ionescu R., Forsea A.M., Tanaseanu C., Dumitrache S., Otelea D., Tamsulea I., Tanaseanu S., Chitonu C., Paraschiv S., Balteanu M., Stefanescu M., Matache C. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009, 42:41-49.
15. Radstake T.R., van Bon L., Broen J., Hussiani A., Hesselstrand R., Wuttge D.M., Deng Y., Simms R., Lubberts E., Lafyatis R. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009, 4:e5903.
16. Murata M., Fujimoto M., Matsushita T., Hamaguchi Y., Hasegawa M., Takehara K., Komura K., Sato S. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J. Dermatol. Sci. 2008, 50:240-242.
17. Biagi E., Di Biaso I., Leoni V., Gaipa G., Rossi V., Bugarin C., Renoldi G., Parma M., Balduzzi A., Perseghin P., Biondi A. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007, 84:31-39.
18. Bladon J., Taylor P. Extracorporeal photopheresis normalizes some lymphocyte subsets (including T regulatory cells) in chronic graft-versus-host-disease. Ther. Apher. Dial. 2008, 12:311-318.
19. Di Biaso I., Di Maio L., Bugarin C., Gaipa G., Dander E., Balduzzi A., Parma M., D'Amico G., Perseghin P., Biondi A., Biagi E. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation 2009, 87:1422-1425.
20. Arend W.P., Guthridge C.J. Biological role of interleukin 1 receptor antagonist isoforms. Ann. Rheum. Dis. 2000, 59(Suppl. 1):i60-i64.
21. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
22. Needleman B.W., Wigley F.M., Stair R.W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum. 1992, 35:67-72.
23. Sakkas L.I., Chikanza I.C., Platsoucas C.D. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat. Clin. Pract. Rheumatol. 2006, 2:679-685.
24. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Jung S., Chimenti S., Landsman L., Abramovitch R., Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124:175-189.
25. Hummers L.K., Hall A., Wigley F.M., Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J. Rheumatol. 2009, 36:576-582.
26. Kawaguchi Y., Harigai M., Hara M., Fukasawa C., Takagi K., Tanaka M., Tanaka E., Nishimagi E., Kamatani N. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J. Rheumatol. 2002, 29:1877-1883.